Terms: = Thyroid cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
430 results:
1. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
[TBL] [Abstract] [Full Text] [Related]
2. Diagnostic Performance of [
Ventura D; Dittmann M; Büther F; Schäfers M; Rahbar K; Hescheler D; Claesener M; Schindler P; Riemann B; Seifert R; Roll W
J Nucl Med; 2024 Feb; 65(2):192-198. PubMed ID: 38164565
[TBL] [Abstract] [Full Text] [Related]
3. All-Cause and Cause-Specific Mortality Among Low-Risk Differentiated thyroid cancer Survivors in the United States.
Tran TV; Schonfeld SJ; Pasqual E; Haymart MR; Morton LM; Kitahara CM
Thyroid; 2024 Feb; 34(2):215-224. PubMed ID: 38149602
[No Abstract] [Full Text] [Related]
4. Social Vulnerability Association with thyroid cancer Disparities in the United States.
Fei-Zhang DJ; Verma R; Arimoto R; Lawrence AS; Chelius DC; Patel UA; Smith SS; Sheyn AM; Rastatter JC
Thyroid; 2024 Feb; 34(2):225-233. PubMed ID: 38069566
[No Abstract] [Full Text] [Related]
5. Increased Progression-Free Survival with Cabozantinib Versus Placebo in Patients with Radioiodine-Refractory Differentiated thyroid cancer Irrespective of Prior Vascular Endothelial Growth Factor Receptor-Targeted Therapy and Tumor Histology: A Subgroup Analysis of the COSMIC-311 Study.
Capdevila J; Krajewska J; Hernando J; Robinson B; Sherman SI; Jarzab B; Lin CC; Vaisman F; Hoff AO; Hitre E; Bowles DW; Williamson D; Levytskyy R; Oliver J; Keam B; Brose MS
Thyroid; 2024 Mar; 34(3):347-359. PubMed ID: 38062732
[No Abstract] [Full Text] [Related]
6. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
Ho AL; Foster NR; Deraje Vasudeva S; Katabi N; Antonescu CR; Frenette GP; Pfister DG; Erlichman C; Schwartz GK
Cancer; 2024 Mar; 130(5):702-712. PubMed ID: 37947157
[TBL] [Abstract] [Full Text] [Related]
7. Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [
Günther T; Holzleitner N; Viering O; Beck R; Wienand G; Dierks A; Pfob CH; Bundschuh RA; Kircher M; Lapa C; Wester HJ
J Nucl Med; 2024 Jan; 65(1):33-39. PubMed ID: 37945383
[TBL] [Abstract] [Full Text] [Related]
8. Phase 3 Trial of Selpercatinib in Advanced
Hadoux J; Elisei R; Brose MS; Hoff AO; Robinson BG; Gao M; Jarzab B; Isaev P; Kopeckova K; Wadsley J; Führer D; Keam B; Bardet S; Sherman EJ; Tahara M; Hu MI; Singh R; Lin Y; Soldatenkova V; Wright J; Lin B; Maeda P; Capdevila J; Wirth LJ;
N Engl J Med; 2023 Nov; 389(20):1851-1861. PubMed ID: 37870969
[TBL] [Abstract] [Full Text] [Related]
9. Early Increases in Blood Pressure and Major Adverse Cardiovascular Events in Patients With Renal Cell Carcinoma and thyroid cancer Treated With VEGFR TKIs.
Narayan V; Liu T; Song Y; Mitchell J; Sicks J; Gareen I; Sun L; Denduluri S; Fisher C; Manikowski J; Wojtowicz M; Vadakara J; Haas N; Margulies KB; Ky B
J Natl Compr Canc Netw; 2023 Oct; 21(10):1039-1049.e10. PubMed ID: 37856199
[TBL] [Abstract] [Full Text] [Related]
10. Efficacy of HIFU for the treatment of benign thyroid nodules: a systematic review and meta-analysis.
Fan KY; Loh EW; Tam KW
Eur Radiol; 2024 Apr; 34(4):2310-2322. PubMed ID: 37792080
[TBL] [Abstract] [Full Text] [Related]
11. Pharmacokinetics/Pharmacodynamics of Dabrafenib and Trametinib for Redifferentiation and treatment of Radioactive Iodine-Resistant Mutated Advanced Differentiated thyroid cancer.
Balakirouchenane D; Seban R; Groussin L; Puszkiel A; Cottereau AS; Clerc J; Vidal M; Goldwasser F; Arrondeau J; Blanchet B; Huillard O
Thyroid; 2023 Nov; 33(11):1327-1338. PubMed ID: 37725566
[No Abstract] [Full Text] [Related]
12. Fulvestrant with or without anti-HER2 therapy in patients in a postmenopausal hormonal state and with ER-positive HER2-positive advanced or metastatic breast cancer: A subgroup analysis of data from the Safari study (JBCRG-C06).
Masuyama M; Masuda N; Kawaguchi H; Yamamoto Y; Saji S; Nakayama T; Aogi K; Anan K; Ohtani S; Sato N; Takano T; Tokunaga E; Nakamura S; Hasegawa Y; Hattori M; Fujisawa T; Morita S; Yamaguchi M; Yamashita T; Yotsumoto D; Toi M; Ohno S
Cancer Med; 2023 Sep; 12(17):17718-17730. PubMed ID: 37525895
[TBL] [Abstract] [Full Text] [Related]
13. Is unicentric familial papillary thyroid microcarcinoma different from multicentric?
Ríos A; Ruiz-Pardo J; Balaguer-Román A; Puñal JA; Moreno P; Mercader E; Ferrero E; Morlán MA; Martín J; Durán M; Bravo JM; Casanova D; Salvador-Egea MP; Torregrosa NM; Exposito-Rodríguez A; Martínez-Fernández G; Carrión AM; Vidal O; Herrera F; Ruiz-Merino G; Rodríguez JM
Endocrine; 2023 Dec; 82(3):613-621. PubMed ID: 37490266
[TBL] [Abstract] [Full Text] [Related]
14. Comparison of the Efficiency of Radiofrequency and Microwave Ablation Methods in the treatment of Benign thyroid Nodules.
Cerit MN; Yücel C; Cerit ET; Yalçın MM; Şendur HN; Oktar SÖ
Acad Radiol; 2023 Oct; 30(10):2172-2180. PubMed ID: 37357048
[TBL] [Abstract] [Full Text] [Related]
15. Phase I study of MSB2311, a novel pH-dependent anti-PD-L1 monoclonal antibody, treating patients with advanced solid tumors and lymphoma.
Zhang Q; Zhang J; Zhong H; Yuan Y; Yang L; Zhang Q; Ji D; Gong J; Li J; Yao Z; Qi C; Wang J; Lu L; Shi M; Qian X; Shen L; Li J; Hu X
Cancer Immunol Immunother; 2023 Aug; 72(8):2729-2739. PubMed ID: 37115210
[TBL] [Abstract] [Full Text] [Related]
16. Diabetes care cascade and associated factors in 10 700 middle-aged adults in four sub-Saharan African countries: a cross-sectional study.
Wade AN; Maposa I; Agongo G; Asiki G; Boua P; Choma SSR; Gómez-Olivé FX; Maimela E; Micklesfield LK; Mohamed SF; Nonterah EA; Norris SA; Sorgho H; Ramsay M; Crowther NJ;
BMJ Open; 2023 Apr; 13(4):e069193. PubMed ID: 37105688
[TBL] [Abstract] [Full Text] [Related]
17. Dabrafenib plus trametinib in BRAFV600E-mutated rare cancers: the phase 2 ROAR trial.
Subbiah V; Kreitman RJ; Wainberg ZA; Gazzah A; Lassen U; Stein A; Wen PY; Dietrich S; de Jonge MJA; Blay JY; Italiano A; Yonemori K; Cho DC; de Vos FYFL; Moreau P; Fernandez EE; Schellens JHM; Zielinski CC; Redhu S; Boran A; Passos VQ; Ilankumaran P; Bang YJ
Nat Med; 2023 May; 29(5):1103-1112. PubMed ID: 37059834
[TBL] [Abstract] [Full Text] [Related]
18. Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis.
Zhi WI; Dreyfus N; Lessing A; Galantino M; Piulson L; Kot KL; Li S; Bao T
Oncologist; 2023 Jul; 28(7):604-608. PubMed ID: 36972359
[TBL] [Abstract] [Full Text] [Related]
19. Adverse birth outcomes of adolescent and young adult women diagnosed with cancer during pregnancy.
Betts AC; Shay LA; Lupo PJ; Pruitt SL; Roth ME; Allicock MA; Cohn BA; Murphy CC
J Natl Cancer Inst; 2023 Jun; 115(6):619-627. PubMed ID: 36912709
[TBL] [Abstract] [Full Text] [Related]
20. The World Trade Center Health Program: cancer screening and cancer care best practices.
Calvert GM; Lilly G; Cochran J
Arch Environ Occup Health; 2023; 78(4):222-228. PubMed ID: 36908247
[TBL] [Abstract] [Full Text] [Related]
[Next]
